Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Medical Solutions Group Regulatory News (AMS)

Share Price Information for Advanced Medical Solutions Group (AMS)

Share Price is delayed by 15 minutes
Get Live Data
219.00    0.00 (0.00%)
Bid:
218.50
Ask:
219.50
Spread: 1.00 (0.458%)
Market Cap: £475.74m
AMS Live PriceLast checked at - London Stock Exchange

Intraday Advanced Medical Solutions Group Share Chart

Rule 2.9 Announcement

8 Jun 2026 14:25

RNS Number : 4477H
Advanced Medical Solutions Grp PLC
08 June 2026
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

FOR IMMEDIATE RELEASE

8 June 2026

 

Advanced Medical Solutions Group plc("AMS")

 

Rule 2.9 Announcement

 

In accordance with Rule 2.9 of The City Code on Takeovers and Mergers (the "Code"), AMS confirms that, as at the date and time of this announcement, it had 220,435,551 ordinary shares of 5 pence each in issue and admitted to trading on the AIM Market of the London Stock Exchange. AMS does not hold any ordinary shares in treasury. Therefore, the total number of shares with full voting rights in AMS at the above date was 220,435,551.

The International Securities Identification Number (ISIN) for AMS' ordinary shares is GB0004536594 and AMS' LEI number is 213800HJP6OWOSZI1L74.

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Tel: +44 (0) 1606 545508

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTUWUORNUUNRAR
Date   Source Headline
31st Jul 20201:29 pmRNSTotal Voting Rights
9th Jul 20207:00 amRNSTrading Update
30th Jun 20205:52 pmRNSTotal Voting Rights
19th Jun 202012:02 pmRNSPrice Monitoring Extension
15th Jun 202012:02 pmRNSPrice Monitoring Extension
10th Jun 202011:30 amRNSResult of Annual General Meeting
10th Jun 20207:00 amRNSAGM Trading and US LiquiBand® Update
29th May 20202:17 pmRNSTotal Voting Rights
18th May 20207:00 amRNSAnnual Report, AGM and Board Change
12th May 20206:16 pmRNSDirector/PDMR Shareholding
11th May 20204:01 pmRNSDirector/PDMR Shareholding
30th Apr 20202:00 pmRNSTotal Voting Rights
17th Apr 20204:30 pmRNSDirector/PDMR Shareholding
14th Apr 20207:00 amRNSPCA Dealing
6th Apr 20209:26 amRNSDirector/PDMR and PCA Shareholding
6th Apr 20207:01 amRNSClinical Development Programme
6th Apr 20207:00 amRNSDirector/PDMR Shareholding
2nd Apr 20207:00 amRNSCOVID-19 Update
30th Mar 20209:06 amRNSHoldings in Company
13th Mar 20205:00 pmRNSHolding(s) in Company
11th Mar 20207:00 amRNSUnaudited Preliminary Results
10th Mar 20207:00 amRNSBlock listing Interim Review
10th Mar 20207:00 amRNSFDA Approval of LiquiBand® Rapid(TM)
11th Feb 202010:03 amRNSHolding(s) in Company
15th Jan 20207:00 amRNSYear End Trading Update
31st Dec 201912:18 pmRNSTotal Voting Rights
2nd Dec 20197:00 amRNSAcquisition of Biomatlante SA
29th Nov 20193:08 pmRNSTotal Voting Rights
29th Nov 20197:00 amRNSThird party sterilisation failure
31st Oct 20193:13 pmRNSTotal Voting Rights
31st Oct 20193:09 pmRNSHolding(s) in Company
16th Sep 201911:15 amRNSHolding(s) in Company
16th Sep 20197:00 amRNSDirector/PDMR Shareholding
11th Sep 20197:00 amRNSInterim Results
6th Sep 20197:00 amRNSBlock listing Interim Review
8th Aug 20197:00 amRNSNotice of Interim Results
31st Jul 20195:52 pmRNSTotal Voting Rights
30th Jul 20197:00 amRNSFDA approval for two advanced woundcare ranges
28th Jun 20192:23 pmRNSTotal Voting Rights
21st Jun 20197:00 amRNSTrading Update
5th Jun 20195:29 pmRNSResult of AGM
5th Jun 20197:00 amRNSNotice of AGM
31st May 20193:10 pmRNSTotal Voting Rights
14th May 20197:00 amRNSIDE received for LiquiBand Fix8 in US
30th Apr 20194:56 pmRNSTotal Voting Rights
30th Apr 20199:40 amRNSNotice of Annual General Meeting and Annual Report
29th Apr 20195:27 pmRNSDirector/PDMR Shareholding
4th Apr 201910:16 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSHolding(s) in Company
13th Mar 20197:00 amRNSUnaudited preliminary results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.